lactobacillus fermentum TSF331

**Lactobacillus fermentum TSF331** is a probiotic bacterial strain developed for potential therapeutic use in metabolic disorders. The strain has been studied for its ability to assimilate purine nucleosides, particularly inosine and guanosine, which leads to a reduction in serum uric acid (UA) levels. In animal models of hyperuricemia, TSF331 decreased serum UA by approximately 30% and demonstrated strong in vitro purine assimilation properties. Clinical studies in humans have also shown that supplementation with TSF331, alone or in combination with other probiotic strains, significantly improves liver function markers (AST, ALT) and lowers serum UA levels, and promotes healthier gut microbiota composition. The mechanism of action includes the metabolism of purine derivatives, potentially leading to reduced substrate for uric acid production and enhanced uric acid excretion. TSF331 is currently being investigated as a dietary probiotic intervention for metabolic-associated fatty liver disease (MAFLD) and hyperuricemia. No significant adverse effects have been reported in preclinical or early clinical studies[1][2][3][4][5].